Plexxikon
Biotechnology, 329 Oyster Pt BLVD, South San Francisco, California, 94080, United States, 51-200 Employees
Phone Number: 51********
Who is PLEXXIKON
Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery ...
Read More
-
Headquarters: 329 Oyster Pt BLVD, South San Francisco, California, 94080, United States
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621111 |
Show More
Plexxikon Org Chart and Mapping
Email
Phone
Similar Companies to Plexxikon
Ambagon Therapeutics
-
11-50
-
$ 5 Million to 10 Million
Biomea Fusion
-
51-200
-
$ 10 Million to 25 Million
Frontier Medicines
-
51-200
-
$ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Plexxikon
Answer: Plexxikon's headquarters are located at 329 Oyster Pt BLVD, South San Francisco, California, 94080, United States
Answer: Plexxikon's phone number is 51********
Answer: Plexxikon's official website is https://plexxikon.com
Answer: Plexxikon's revenue is $25 Million to $50 Million
Answer: Plexxikon's SIC: 2834
Answer: Plexxikon's NAICS: 621111
Answer: Plexxikon has 51-200 employees
Answer: Plexxikon is in Biotechnology
Answer: Plexxikon top competitors include: Ambagon Therapeutics , Biomea Fusion , Frontier Medicines
Answer: Plexxikon contact info: Phone number: 51******** Website: https://plexxikon.com
Answer: Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikons platform enables the design of highly selective and targeted medicines, supporting the companys broader strategy to develop personalized medicines. In 2005, Plexxikon scientists discovered ZELBORAF (vemurafenib) tablets, formerly known as PLX4032, and initiated the first clinical trial in 2006. Together with its partner Roche, Plexxikon co-developed this mutation-specific medicine, in less than five years. A companion diagnostic used to determine ZELBORAF treatment eligibility was approved at the same time. ZELBORAF has been approved in over 40 countries worldwide. Plexxikon's demonstrated capability in discovery and early development, as well as its diverse pipeline, uniquely positions the company to develop multiple commercial franchises for different therapeutic indications, and create significant value for Plexxikon and its collaborators. Plexxikon's novel discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnerships that support later stage development, have been key drivers of the company's success since it began operations in 2001.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month